Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece (Q34266016)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

1 August 2017

Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece (English)

1 reference

Europe PubMed Central

1 August 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

cost-effectiveness analysis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Charalampos Tzanetakos

1

1 reference

Europe PubMed Central

1 August 2017

Andreas Melidonis

2

1 reference

Europe PubMed Central

1 August 2017

Christos Verras

3

1 reference

Europe PubMed Central

1 August 2017

Georgia Kourlaba

4

1 reference

Europe PubMed Central

1 August 2017

Nikos Maniadakis

5

1 reference

Europe PubMed Central

1 August 2017

publication date

22 September 2014

1 reference

Europe PubMed Central

1 August 2017

BMC Health Services Research

1 reference

Europe PubMed Central

1 August 2017

14

1 reference

Europe PubMed Central

1 August 2017

419

1 reference

Europe PubMed Central

1 August 2017

https://scigraph.springernature.com/pub.10.1186/1472-6963-14-419

0 references

Incretin therapy for type 2 diabetes in Spain: a cost-effectiveness analysis of liraglutide versus sitagliptin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4179852

6 July 2018

Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4179852

6 July 2018

Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4179852

6 July 2018

An overview of the pharmacokinetics, efficacy and safety of liraglutide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4179852

6 July 2018

The worldwide epidemiology of type 2 diabetes mellitus--present and future perspectives

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4179852

6 July 2018

Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4179852

6 July 2018

Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4179852

6 July 2018

One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label tr

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4179852

6 July 2018

Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4179852

6 July 2018

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4179852

6 July 2018

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4179852

6 July 2018

Glucose control and vascular complications in veterans with type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4179852

6 July 2018

Effects of intensive glucose lowering in type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4179852

6 July 2018

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4179852

6 July 2018

Economic evaluation of treatment strategies for patients suffering acute myocardial infarction in Greece

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4179852

6 July 2018

The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4179852

6 July 2018

Assessing the impact of complications on the costs of Type II diabetes.

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-14-419

21 January 2018

Estimating the direct cost of Type 2 diabetes in Greece: the effects of blood glucose regulation on patient cost

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-14-419

21 January 2018

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-14-419

21 January 2018

Trends in the management of type 2 diabetes and its prescription drug costs in Greece (1998 & 2006).

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-14-419

21 January 2018

Cost-effectiveness analysis of ranibizumab versus verteporfin photodynamic therapy, pegaptanib sodium, and best supportive care for the treatment of age-related macular degeneration in Greece.

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-14-419

21 January 2018

Clopidogrel versus aspirin in patients with atherothrombosis: a CAPRIE-based cost-effectiveness model for Greece

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-14-419

21 January 2018

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-14-419

21 January 2018

Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25245666

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Economic evaluation of hemodialysis: implications for technology assessment in Greece

1 reference

https://pubmed.ncbi.nlm.nih.gov/25245666

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Validation of the CORE Diabetes Model against epidemiological and clinical studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/25245666

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The epidemiology of Type 2 diabetes mellitus in Greek adults: the ATTICA study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25245666

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1472-6963-14-419

1 reference

Europe PubMed Central

1 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34266016&oldid=1873732967"